Apr 23, 2020
Elysium Health(TM) Announces Exclusive License of DNA Methylation Biomarkers of Personalized Health and Aging and Cellular Senescence from Yale University
Mar 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
Nov 06, 2019
Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
Sep 05, 2019
Theragnostics Signs Agreement with AstraZeneca
Jun 05, 2019
Global Longevity and Anti-senescence Therapy Market
May 30, 2019
Longevity and Anti-Senescence Therapy Market, 2023 - Emphasis on Stem Cell Research and Increasing demand for Cell-Based Assays
Mar 31, 2019
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Nov 08, 2018
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Aug 01, 2018
Yeast Still Grow - But Can't Always Breed - When Their Sixteen Chromosomes Are Fused into Two
May 24, 2018
New Review of DNA Damage Response - An Emerging Target for Groundbreaking Cancer Therapies - touchONCOLOGY
May 09, 2018
Allen Integrated Cell released online
Mar 19, 2018
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing
Aug 17, 2017
UNITY Biotechnology Announces Extension of Series B Financing Bringing Total Round to $151 Million